Uncategorized Archives - Page 31 of 251

TuesdayNov 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at…

MondayNov 28, 2022 12:00 pm

Lift Events & Experiences to Bring Unique Cannabis Conference, Trade Show and Associated Opportunities to the U.S. Cannabis Market

Become a part of the 2023 U.S. debut of Lift Events & Experiences, at the Moscone Center in San Francisco, from Wednesday, August 2 – Friday, August 4, 2023. The leader in Canada, Lift’s first conference over the border offers exclusive content, robust networking, and unparalleled new product discovery opportunities. The event is dedicated to the evolution of the cannabis industry, and brings to the U.S. Lift’s long-established and respected reputation for powerful cannabis events. After proving its mettle in Vancouver and Toronto, the former Lift&Co. Expo will now simply be called ‘Lift’, reflecting its expanding footprint. Lift invites attendees…

MondayNov 28, 2022 10:30 am

REZYFi, Inc. Leverages Growth of California’s Cannabis Market as It Expands to Include Social Equity Provisions, More Opportunities for Business Owners

California retail stores sold almost $5.3 billion worth of cannabis products in 2021 and reported a total tax revenue of approximately $1.3 billion California’s three licensing authorities issued 12,227 commercial cannabis licenses to businesses throughout the state during 2021 San Diego has approved a social-equity program, joining the ranks of other California cities and counties that have implemented them since 2018, utilizing tax revenues from the cannabis industry REZYFi is the first cannabis mortgage company in the United States – a market where most traditional lenders are still reticent to enter On November 8, 2016, California voters approved cannabis for…

WednesdayNov 23, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia

Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementia The animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancements Previous independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairment The laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023…

TuesdayNov 22, 2022 12:45 pm

REZYFi, Inc. Continues to See Opportunity in Serving Cannabis-Related Companies Amid Marijuana Rescheduling Efforts in the US

REZYFi is a Miami, Florida-headquartered growth mortgage origination and specialized financing company that primarily targets licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies Traditional banks are governed by federal law, which criminalizes marijuana; as a result, they are hesitant to offer financial services to cannabis businesses The President recently set a process in motion that could culminate in the rescheduling of marijuana, although given that this review will not actually decriminalize the substance, the status quo, which disadvantages cannabis companies, will remain REZYFi believes cannabis-related companies will continue to experience difficulties accessing financing…

MondayNov 21, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetes Lexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertension So far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build…

FridayNov 18, 2022 4:20 am

420 with CNW — NJ Governor Teams Up with Cannabis Firms to Discourage Consuming Black Market Marijuana

The past two decades have seen dozens of American states legalize cannabis for medical and recreational purposes. Cannabis has since proven to be one of the fastest-growing industries in the country, generating billions of dollars in sales and creating hundreds of thousands of new employment opportunities. However, even though the United States is now home to thousands of legal cannabis businesses, the illicit marijuana market still thrives. Data shows that in 2019 black market sellers sold around $8.7 billion worth of cannabis in California, the country’s largest marijuana market compared to $3.1 billion worth of legal sales. Illegal cannabis cultivation…

ThursdayNov 17, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Approved to Proceed with Human Study Evaluating Effectiveness of Patented DehydraTECH(TM) Technology in Boosting Oral-Tissue Absorption of Nicotine

Lexaria Bioscience recently received Independent Review Board approval for its upcoming human clinical nicotine study, NIC-H22-1, and expects to begin dosing soon The company hopes to evidence that processing purified nicotine with its patented DehydraTECH(TM) drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to leading brands currently available on the market, On! and Zyn Last year, Lexaria conducted an animal study evaluating oral nicotine absorption, NIC-A21-1, in which it evidenced that its DehydraTECH technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched…

FridayNov 11, 2022 9:00 am

Zacks SCR Uses Lexaria Bioscience Corp. (NASDAQ: LEXX) HYPER-H21-4 Study to Support $15 Share Valuation

Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placebo According to a Zacks SCR report, the findings support their $15 share valuation of the company Zacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral products The hypertension drug market is expected to grow to over $34 billion through 2030, with North America anticipated to hold 35% of the market share According to the World Health Organization (“WHO”), approximately 1.13 billion people worldwide suffer from hypertension (high blood pressure), with only one…

ThursdayNov 10, 2022 11:15 am

Specialized Market Lender REZYFi, Inc. Believes They Have Real Opportunity Amid Challenges Faced by Traditional Lenders

While economies worldwide are struggling to control spiking inflation rates, REZYFi, a mortgage lender servicing non-traditional as well as other loans, sees unique financial opportunities Through the use of proprietary automated machine learning and associated technologies, together with preparations to launch a high-margin cannabis division later this year to serve an industry in need of loan origination options, REZYFi is working to grow its operation RZFI is licensed in more than 30 U.S. states and expects to expand its loan origination services to all remaining states in coming months Economic challenges resulting from governmental efforts to tame inflation could in…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

Category: Uncategorized